MedPath

Subtotal integumentectomy for treatment of malignant melanoma with indocyanine green(ICG)

Phase 1
Recruiting
Conditions
malignant melanoma
Registration Number
JPRN-UMIN000035972
Lead Sponsor
Faculty of Life Sciences, Kumamoto University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

Subjects have a history of severe hypersensitivity and side effects in Indocyanine green (ICG). Subjects suffer from malignant tumors within 5 years. Subjects suffer from acute myocardial infarction, unstable angina, myocarditis, cerebral infarction within 3 months. Subjects have remarkably unstable circulation dynamics due to severe heart failure, arrhythmia, etc. Subject has active infection. Subjects may be pregnant or pregnant Subject's serum albumin is less than 2g/dl. We can not identify lymph flow with ICG during surgery. In addition, when the doctor in charge judges the subject as inappropriate.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath